Phase I-Ib trial of tivantinib in combination with carboplatin and pemetrexed as first-line treatment in patients (pts) with advanced nonsquamous NSCLC or malignant pleural mesothelioma (MPM).

Authors

Paolo A. Zucali

Humanitas Cancer Center, Rozzano, Italy

Paolo A. Zucali , Matteo Simonelli , Fabio De Vincenzo , Giuseppe Fatuzzo , Monica Bertossi , Matteo B. Suter , Matteo Perrino , Laura Giordano , Armando Santoro

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Phase I trial of tivantinib  in combination with carboplatin and pemetrexed as first-line treatment in patients with advanced nonsquamous non small cell lung cancer or malignant pleural mesothelioma.

First Author: Paolo Andrea Zucali

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)

First Author: Tony Mok

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Phase II results of ivonescimab (AK112/ SMT112), a novel PD-1/VEGF bispecific, in combination with chemotherapy for first line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA) in EGFR/ALK.

First Author: Li Zhang

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.

First Author: Martin Reck